Tissue transglutaminase: a new target to reverse cancer drug resistance

Cancer resistance mechanisms, which result from intrinsic genetic alterations of tumor cells or acquired genetic and epigenetic changes, limit the long-lasting benefits of anti-cancer treatments. Tissue transglutaminase (TG2) has emerged as a putative gene involved in tumor cell drug resistance and...

Descripción completa

Detalles Bibliográficos
Autores principales: Budillon, Alfredo, Carbone, Carmine, Di Gennaro, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2011
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535412/
https://www.ncbi.nlm.nih.gov/pubmed/22130737
http://dx.doi.org/10.1007/s00726-011-1167-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535412/
https://www.ncbi.nlm.nih.gov/pubmed/22130737
http://dx.doi.org/10.1007/s00726-011-1167-9

Ejemplares similares